Abicipar pegol—a novel anti-VEGF therapy with a long duration of action
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Rates of inflammation with abicipar pegol dropped from roughly 15% in the CEDAR and SEQUOIA clinical trials to 8.9% in the MAPLE clinical trial after reformulation [49, 50].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
Krohne, T. U., Liu, Z., Holz, F. G., & Meyer, C. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.047 · Cited by 238
Rodrigues, G. A., Mason, M., Christie, L.-A., Hansen, C., Hernandez, L. M., Burke, J., Luhrs, K. A., & Hohman, T. C. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-25307 · Cited by 74
Callanan, D., Kunimoto, D., Maturi, R. K., Patel, S. S., Staurenghi, G., Wolf, S., Cheetham, J. K., Hohman, T. C., Kim, K., López, F. J., et al. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0062 · Cited by 73 · cited 1×
“The REACH study [3] was a phase II multicenter randomized controlled trial that compared abicipar 1 mg, abicipar 2 mg, and ranibizumab in patients with naïve neovascular AMD.”
MethodKunimoto, D. Y., Ohji, M., Maturi, R. K., Sekiryu, T., Wang, Y., Pan, G., Li, X., Schneider, S., & Groups, F. T. B. A. C. S. (2019) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20190129-13 · Cited by 28
Cited by
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab
Baumal, C. R., Spaide, R. F., Vajzovic, L., Freund, K. B., Walter, S. D., John, V., Rich, R., Chaudhry, N., Lakhanpal, R. R., Oellers, P. R., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.04.017 · Cited by 312
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Liberski, S., Wichrowska, M., & Kocięcki, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169424 · Cited by 139
“However, despite the promising anatomical and functional results from the 12-week injection regimen [96], a high percentage of sterile endophthalmitis was noted during phase III clinical trials in nAMD patients [95], hence the 2020 FDA rejected abicipar pegol as an nAMD drug.”
BackgroundInflammatory Complications of Intravitreal Anti-VEGF Injections
Cox, J. T., Eliott, D., & Sobrin, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050981 · Cited by 137
Metadata
- Authors
- Moisseiev, E., & Loewenstein, A.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Moisseiev, Elad
- Venue
- Eye
- Published
- 2019-09-19
- Volume
- 34
- Issue
- 4
- Pages
- 605-606
- ISSN
- 0078-5334 (ISSN-L)
- 0950-222X
- 1476-5454
- PMC
- PMC7265438
- OpenAlex
- W2973705051
- Cited by
- 36
- References
- 4
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 3 · 2022: 9 · 2021: 8 · 2020: 11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Eye (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- anti-VEGF therapy, vascular endothelial growth factor, intravitreal injection, retinal disease, neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, duration of drug action
- MeSH terms
- Bevacizumab, Humans, Recombinant Fusion Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abicipar pegol—a novel anti-VEGF therapy with a long duration of action. https://app.cochat.ai/papers/10.1038/s41433-019-0584-y
- The paper
- Moisseiev, E., & Loewenstein, A. (2020). Abicipar pegol—a novel anti-VEGF therapy with a long duration of action. Eye. https://doi.org/10.1038/s41433-019-0584-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.